Introduction
While there is a growing number of studies using eventrelated potentials (ERP) for assessment of pain [1] [2] [3] [4] , many questions remain uncovered in this area of research, e.g., ERPs have not yet been applied for the assessment of dose-related analgesic effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Thus, the present study aimed to close this gap. Among NSAIDs ibuprofen was chosen as a potent analgesic the doserelated analgesic effects of which have been studied intensively in a clinical setting [5, 6] . The present investigation included the testing of placebo and two doses of rac-ibuprofen (400 and 800 mg). The drug's absorption was controlled by analysis of rac-ibuprofen plasma concentrations.
Phasic chemical stimulation of the nasal mucosa with carbon dioxide (CO2) was employed as an established model for experimental pain. This technique has been applied in the investigation of a number of centrally acting analgesics [4, 7, 8] . In addition to the phasic painful stimuli, dry air was used as a long-lasting, tonic painful stimulus [9] . The parameters recorded in this study not only included chemo-somatosensory event-related potentials (CSSERP) in response to phasic painful stimulation but also the subjects' ratings of the stimulus intensity. To control for possible non-specific effects of ibuprofen, ERPs to acoustical stimuli, the subjects' performance in a tracking task, and the ratings for sedationrelated symptoms (e.g., 'tiredness,' 'drowsiness') were assessed.
Methods
Eighteen healthy volunteers (nine male and nine female, aged between 22-37 years, mean age 25.8 years) participated in the experiments after they had provided written informed consent. The study was approved by the Ethics Committee of the medical faculty of the University of Erlangen-Niimberg. Acoustically event-related potentials (AERP) A double-blind, randomized, placebo-controlled threefold cross-over design was chosen. Thus, the subjects participated in three experiments separated by at least 7 days. In each experiment the medication (i.e., either placebo, 400 or 800 mg rac-ibuprofen [Aktren®]) was administered orally in two capsules together with 100 ml tap water. Subjects were requested to abstain from solid food for at least 8 h before commencement of measurements. The experiments consisted of two sessions. The first session took place before administration of the medication, and the second 90 min after. This schedule was chosen because rac-ibuprofen reaches its highest plasma concentrations approximately 60-90 min after administration [10] . During the experiments subjects were comfortably seated in an air conditioned room. White noise of approximately 50 dB HL was used to mask switching clicks of the chemical stimulator (ERA stimulator, Horniss & Zeissberg, FRG).
In an additional training session prior to the actual experiments subjects became acquainted with the experimental procedures, and, specifically, with a breathing technique which avoids respiratory flow inside the nasal cavity during stimulation (velopharyngeal closure [11] ).
Painful stimulation of the nasal mucosa
For painful stimulation, tonic and phasic stimuli were applied heterotopically to the left and right nasal cavities, i.e., long-lasting pain was induced in the left nostril while short pulses of painful stimuli were delivered to the right nostril. Tonic painful stimulation [9] was produced by means of a dry airstream of controlled temperature and flow rate (220 C, 145 ml s-1).
The airstream was delivered throughout the sessions starting 5 min before the beginning of each session. Subjects reported a dull or burning pain which reached its steady state within a few minutes. As a rule, both the slight swelling induced by this procedure and the pain from the nasal mucosa decreased immediately after termination of the stimulation and was completely gone within 1 h [9] . In order to elicit phasic painful sensations, CO2 was applied to the right nostril (stimulus duration 200 ms, interval approximately 40 s). As described previously [12, 13] Intensity estimates of painful stimuli After presentation of each phasic stimulus, subjects estimated the perceived intensity in relation to a standard stimulus (65% v/v C02) applied at the beginning of the first session. The painful intensity was rated by means of a visual analogue scale (VAS) displayed on a computer monitor [4] . The intensity of the standard was defined as 100 Estimation Units (100 EU). The intensity of the tonic painful sensation was reported in a similar manner. However, because the subjects did not receive a standard stimulus prior to the measurements, a different kind of VAS was employed. That is, the scale's left hand end indicated 'no pain' (0 EU) and the right hand end 'unbearable pain' (100 EU). For further statistical evaluation estimates were averaged separately for each session.
Tracking performance
During intervals between phasic painful stimuli, subjects were requested to perform a tracking task on a video screen [4] . Using a joystick they had to keep a small square inside a larger one which moved around at random. By checking how often, and measuring for how long, the subjects had lost track of the independently moving square it was possible to detect changes in the state of vigilance and/or motor coordination (range between 0-100% successful performance in tracking). As with intensity estimates the data were averaged for each session.
Adverse reactions
After each session subjects estimated the intensity of four symptoms ('tiredness,' 'headache,' 'drowsiness,' and 'vertigo') by means of VAS. The left pole of the scales was defined as 'no such symptom' (0 EU) and the right pole as 'symptom experienced at maximum' (100 EU). In addition, all spontaneous reports of the subjects were recorded verbatim.
Plasma concentrations of rac-ibuprofen
In order to control for rate of absorption of racibuprofen, blood samples were drawn through an intravenous catheter 90 min after administration of the medication. Rac-ibuprofen concentrations were measured by h.p.l.c. assay as described by Geisslinger et al. [14] . The limit of quantification consistent with a precision of 10% or less was 0.1 ug ml-'. The coefficient of variation over the calibration range of 0.1-50 ,ug ml-' of rac-ibuprofen was less than 6%. 
Results

Plasma concentrations of rac-ibuprofen
Mean plasma concentrations of rac-ibuprofen obtained 90 min after intake exhibited a dose-related increase indicating regular absorption of the drug (400 mg rac-ibuprofen: mean 28.0 ± 11.7 ,ug ml-'; 800 mg rac-ibuprofen: mean 41.7 ± 18.9 ,ug ml-'). Figure 1 shows CSSERP averaged across all subjects. Due to an excessive number of blink artifacts ERPs could not be analysed in six subjects.
Amplitudes PINI were reduced in a dose-related manner (factor 'dose': F = 3.81, P < 0.05). That is, when compared with placebo, 400 and 800 mg ibuprofen reduced the mean amplitudes PINI by approximately 20 and 30%, respectively (Figure 2 ; Table la ). These changes were most pronounced at the fronto-central recording positions (Fz, Cz). In contrast, the drug-induced decrease of amplitude N1P2 did not reach a statistically significant level.
Although CSSERP latencies tended to increase in relation to the concentration of ibuprofen no significant main effect of the factor 'dose' could be found. However, the statistical interaction between the factors 'dose' and 'recording position' became significant for latencies P1 (F = 2.75, P < 0.05), and Ni (F = 3.26, P < 0.05) emphasizing that CSSERP latencies changed not only in relation to the dosage of ibuprofen but also in relation to the recording sites. In other words, while a dose-related increase of latencies was observed at position Fz these changes were less pronounced at Cz and Pz (Figure 3 ).
AERP
In contrast to the pain-related responses, neither one of the two factors 'dose' or 'recording position' was found to produce a significant effect on AERPs (Table Ib) . the intake of ibuprofen. Moreover, the tracking performance was unaffected by ibuprofen suggesting that the subjects' vigilance was not altered by the medication (Table 2b) .
Discussion
Ibuprofen produced a dose-related decrease in CSSERP amplitudes. It is important to note that the acoustical ERPs, the subjects' tracking performance, and the ratings for 'tiredness' were not significantly affected by ibuprofen. Therefore, it can be assumed that the dose-related decrease in CSSERP amplitudes was likely not due to non-specific effects of ibuprofen such as sedation, but to its analgesic properties. The results also suggest that CSSERP constitutes a more sensitive measure when compared with psychophysically obtained responses. While CSSERP amplitudes significantly decreased in relation to an increase in the dosage of ibuprofen, ratings for both tonic and phasic painful stimuli only exhibited a tendency to decrease in a dose-related manner that did not reach statistical significance. In that respect, the current study confirmed previous reports by Kobal et al. [4] who found that after a single dose administration of aspirin there was a decrease of CSSERP amplitudes accompanied by a mean decrease in intensity estimates of phasic painful stimuli. However, as with the present data, the decrease in the subjects' ratings was not statistically significant.
Regarding the specificity of uncovering a drug's analgesic properties, similar results on CSSERPs have also been obtained in two other studies on 'centrally acting analgesics' [8, 15] . An investigation of flupirtine [8] , a novel centrally acting analgesic, showed that CSSERP amplitudes decreased in a doserelated manner for 100 and 200 mg flupirtine while there was no further decrease for 300 mg. In contrast, intensity estimates of the painful stimuli steadily decreased in relation to an increase of the dose.
However, the decrease of the ratings for 300 mg flupirtine was accompanied by a strong increase of the side effect 'elation in mood' indicating that the decrease in intensity estimates was subject to a nonspecific change in the perception of painful stimuli. In addition, Hummel et al. [15] recently published an investigation of the drugs anpirtoline, tramadol and imipramine all of which have been reported to possess pain-relieving properties. They demonstrated that imipramine reduced estimates of painful stimuli while CSSERP amplitudes remained unchanged. Since imipramine also produced a large increase of the side effect 'sedation,' a decrease in the tracking performance, and an increase in the alpha-band of the spontaneous EEG, it was concluded that the painrelief was not based on antinociceptive effects but rather on non-specific properties of the tricyclic antidepressant. Thus, the present study adds to the cumulative evidence that CSSERPs are a useful tool in the evaluation of analgesic efficacy in humans producing information different from the sole analysis of psychophysics.
It is interesting to note that ibuprofen induced a decrease in CSSERP amplitudes which was most pronounced at the frontal recording sites. Similar results have been obtained by Kobal et al. [4] who observed that aspirin at a dosage of 1000 mg administered orally produced a decrease of CSSERP amplitudes comparable with those produced by 30 mg pentazocine, a partial opioid-receptor agonist/ antagonist, administered intravenously. However, in contrast to the opioid, aspirin failed to induce significant CSSERP changes at parietal recording sites. These results have been interpreted in terms of the possible differential influence of the two drugs, aspirin and pentazocine, on cortical sources responsible for the generation of CSSERP [16] .
Ibuprofen affected the CSSERPs' early amplitude PINI. In light of other studies [17] [18] [19] , this likely indicates that ibuprofen affected exogenous stimulus characteristics (e.g., stimulus intensity) rather than the processsing of endogenous information (e.g. emotional evaluation of the painful stimulus) being represented by later CSSERP components. Thus, the data suggest that ibuprofen activates antinociceptive mechanisms at relatively early stages of the stimulus processing which may include both actions at peripheral receptor sites [20] and antinociceptive activity in the dorsal horn of the spinal cord [21] .
Since CSSERP are generated in response to shortlasting, phasic stimuli, the findings of the present study question the widely accepted view that NSAIDs do not interfere with the perception of phasic painful stimuli which predominantly activate Adelta-fibres [22, 23] . Surprisingly, this view is not based on single fibre recordings but rather on the interpretation of various NSAIDs' actions in different animal models involving the evaluation of reflex mechanisms such as the tail-flick or writhing [24] [25] [26] . Although the effect on Adelta-fibres may not be the predominant pharmacologic action of NSAIDs, the present results add to other findings indicating the presumed action of NSAIDs on Adelta-fibre mediated nociception [27, 28] .
In contrast to CSSERP amplitudes, the ratings for both tonic and phasic pain tended to decrease in a dose-related manner but did not exhibit a significant effect of ibuprofen. This negative result confirms other research in single-dose studies [4, 28] . That is, although the subjects' ratings decreased after drug administration, those studies did not demonstrate a significant effect of so-called antipyretic analgesics on intensity estimates for painful stimuli. However, it has been shown that NSAIDs produce a significant reduction in ERP amplitudes. In line with this, it is likely that pain-related ERPs are a more sensitive measure of analgesia compared with intensity estimates of pain. In other words, compared with ERPs, intensity estimates of painful stimuli appear to exhibit a larger degree of both inter-and intraindividual variability. This may be due to factors such as the subjects' mood, bias, or willingness to respond to painful stimuli.
